Cancer Cytopathology is part of a rich history of scholarly publication which began in 1948 with the launch of Cancer: Interdisciplinary International Journal of the American Cancer Society. The Society’s second journal, CA: A Cancer Journal for Clinicians, was launched just a couple of years later in 1950. And of course, the most recent member of the American Cancer Society Family of Journals, Cancer Cytopathology, began print and online publication in 1997. The American Cancer Society’s commitment and dedication to its journal publishing program has been critical to the success of each of these journals. Our program’s mission is clear:

Cancer Cytopathology’s editorial mission is devoted to the larger program’s goal:

The Society’s journals program accomplishes these two missions by teaming the knowledgeable Editorial Staff (Managing Editors, Editorial Assistants, Business Directors, and others) with a well-known and established commercial publisher, Wiley-Blackwell, as well as clinician-scientists like me, my Associate Editors, and you, our editorial board. It is the joining of these resources that allows us to publish the very best content.

We continue to receive the best cytopathology manuscripts from North America, and increasingly from international sources as well. Future issues will continue to provide our readers with state-of-the-art information. Our review articles and commentaries have been designed to keep our readers current with evolving trends in our discipline.  Please visit our homepage for examples and much more.

In the June 2010 issue, we premiered CytoSource, a section that explores current news and trends in medicine of interest to cytologists, bringing unique, interesting, and important information to our readership. CytoSource goes beyond delivering peer-reviewed research and commentary to report on news and issues that are relevant to readers such as interviews with key individuals in the field, policy updates, information regarding new technology and techniques, and balanced discussions of critical issues in cytopathology.

In August 2011, CytoSource launched its first reader poll intended to take the pulse of our readers concerning important trends and hot topics. CytoSource polls have focused on topics such as ultrasound-guided fine-needle aspiration and the use of social media in pathology. Follow this link to see the results!

In keeping with our mission and the mission of the ACS to provide an interdisciplinary forum for the exchange of knowledge and ideas related to the fields of cytopathology and oncology, for several years the journal has also offered Cancer Cytopathology Complimentary. This online feature showcases newly published online content, selected by me, allowing us to highlight interesting reviews, novel research, or hot new topics. These articles are placed outside the firewall, making them freely available to all readers. Individuals visiting our Web site can access these articles, which are updated on an ongoing basis and showcase the high-quality content published in the journal, by clicking on the Cancer Cytopathology Complimentary icon on the homepage. So, please take a moment to access Cancer Cytopathology online; this will be an evolving site as we bring more enhancements and applications to you throughout the coming months.

The Associate Editors and I triage every submission prior to any review. We pride ourselves on getting papers reviewed quickly so that authors know exactly where they stand and can submit to another journal if their paper does not meet our threshold for acceptance. As we all know, speed as well as quality of review is critical to a journal’s success. Manuscripts submitted to Cancer Cytopathology are reviewed and a decision rendered within 2.5 weeks on average.

Simply said, authors who submit their work to us and pass our rigorous peer review get published faster. Our Editors, Board, and Reviewers are unparalleled in their dedication to rapid turnaround of manuscripts. The chart below illustrates how we stack up with the competition.

For those of you who may not know, none of the ACS Journals charge author fees for submission, page charges, or color figures. And, all content is free online after 12 months. If an author wants to make an article open access upon publication, they can do so for a fee.

We are the top journal in cytopathology, and our impact factor speaks for itself.

Now you can access and share our content anytime, anywhere with our new mobile app for use with all mobile phones and tablets such as iPad. You can get:

1. Instant, real-time access to the latest content from Cancer Cytopathology, as well as the other ACS journals.
2. Ability to read and access content offline as well as save it for later reading.

The app, which is a joint venture of the ACS and Wiley-Blackwell for the ACS Family of Journals, launched in May 2011 and has already been heavily downloaded. If you would like to download the app for your mobile device, go to acs.mwap.at to get it.

Cancer Cytopathology continues its mission to provide cutting edge research in cytopathology as well as high quality reviews and commentaries that tackle current issues and controversies in our discipline.  And, with your continued support and effort, 2012 will be another fantastic year!

Though it began as a section of Cancer, Cancer Cytopathology grew quickly, developing its independence and becoming the premier journal in the field of cytopathology.

In 2005, the American Cancer Society partnered with the American Society of Cytopathology (ASC) to make Cancer Cytopathology their official journal for a period of 6 years. This allowed ASC members to receive the journal at a discounted rate and use the journal to promote the ASC annual meeting. After much consideration, the American Cancer Society decided that it was in the best interest of our journal publishing program to discontinue external society affiliations for all our journals.  

While we are no longer the official journal of the ASC, our publisher has provided a discounted subscription rate to the ASC membership for 2010-2013 so that these readers can continue to have access to our content